A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

Rasonque has entered the medical market as a new pancreatic cancer treatment. It is developed by Revolution Medicines. The drug carries a price tag of $480,000 per year. This high cost illustrates the massive inflation in cancer drug prices. Such price increases have accumulated over the past two decades. Specialized treatments continue to face escalating financial demands. Patients and healthcare systems navigate these rising costs. The situation reflects the emerging financial realities of modern oncology.